NCT03982160Active, not recruitingPhase 4
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
Role of Decreased Nitric Oxide in the Tonic Elevation of Resting Sympathetic Nerve Activity in Chronic Kidney Disease Patients
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. . The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 6 Jun 2019
- Start date
- 1 Feb 2018
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- The University of Texas at Arlington
- Diseases
- Chronic kidney disease
- NCT number
- NCT03982160
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 15
- From 1 Feb 2018 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous organ transplantation
- immunosuppressant therapy
- taking menopausal drugs (estradiol)
Other illness
- myocardial infarction
- heart failure
- cancer with current treatment
- human immunodeficiency virus infection
- resting heart rate ≥ 100 bpm and
Lab values
- anemia (hemoglobin \<8 g/dl)
Other
- pregnancy and/or lactating
- current tobacco use
- treatment for diabetic neuropathy
- systolic blood pressure ≤ 90 mmHg
Who the study is looking for
- CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.
- Men and women 35 to 75 years of age
Age in the registry: 35 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UT Southwestern Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| University of Delaware Coordinator of this site? Confirm its status | Newark | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.